These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 11364417)

  • 21. Liver enzyme elevation after lamivudine withdrawal in HIV-hepatitis B virus co-infected patients: the Swiss HIV Cohort Study.
    Bellini C; Keiser O; Chave JP; Evison J; Fehr J; Kaiser L; Weber R; Vernazza P; Bernasconi E; Telenti A; Cavassini M;
    HIV Med; 2009 Jan; 10(1):12-8. PubMed ID: 18795964
    [TBL] [Abstract][Full Text] [Related]  

  • 22. FDA notifications. Lamivudine/zidovudine combination approved for pediatric use.
    AIDS Alert; 2009 Sep; 24(9):105. PubMed ID: 19938311
    [No Abstract]   [Full Text] [Related]  

  • 23. Abacavir (Ziagen) approval recommended.
    AIDS Treat News; 1998 Nov; (No 306):4. PubMed ID: 11365961
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FDA gives salvage therapy testing a push forward.
    Bass E
    AIDS Treat News; 2001 Mar; (362):3-7, 1. PubMed ID: 11569956
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FDA looks at full approval for d4T. Food and Drug Administration.
    Posit Aware; 1996; 7(1):7. PubMed ID: 11363131
    [TBL] [Abstract][Full Text] [Related]  

  • 26. FDA notifications. FDA approves generic lamivudine.
    AIDS Alert; 2008 Dec; 23(12):142. PubMed ID: 19110688
    [No Abstract]   [Full Text] [Related]  

  • 27. FDA notifications. FDA tentatively approves generic lamivudine.
    AIDS Alert; 2007 May; 22(5):57. PubMed ID: 17580368
    [No Abstract]   [Full Text] [Related]  

  • 28. FDA evaluates accelerated approval process. Food and Drug Administration.
    Common Factor; 1995 Apr; (no 10):18. PubMed ID: 11362343
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FDA notifications. Tentative approval for lamivudine.
    AIDS Alert; 2009 Aug; 24(8):93-4. PubMed ID: 19708084
    [No Abstract]   [Full Text] [Related]  

  • 30. FDA approval of nevirapine for HIV.
    Am Fam Physician; 1996 Oct; 54(5):1805-6. PubMed ID: 8857799
    [No Abstract]   [Full Text] [Related]  

  • 31. FDA notifications. FDA grants tentative approval to two ART drugs under expedited review.
    AIDS Alert; 2007 May; 22(5):57. PubMed ID: 17580369
    [No Abstract]   [Full Text] [Related]  

  • 32. Immune reconstitution hepatitis in HIV and hepatitis B coinfection, despite lamivudine therapy as part of HAART.
    Drake A; Mijch A; Sasadeusz J
    Clin Infect Dis; 2004 Jul; 39(1):129-32. PubMed ID: 15206064
    [TBL] [Abstract][Full Text] [Related]  

  • 33. FDA notifications. Reyataz is approved for HIV treatment.
    AIDS Alert; 2003 Sep; 18(9):119-20. PubMed ID: 14686309
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FDA notifications. FDA approves raltegravir for HIV-1 treatment-naive patients.
    AIDS Alert; 2009 Sep; 24(9):106-7. PubMed ID: 19938313
    [No Abstract]   [Full Text] [Related]  

  • 35. FDA notifications. FDA grants approval for raltegravir.
    AIDS Alert; 2009 Apr; 24(4):46-8. PubMed ID: 19382366
    [No Abstract]   [Full Text] [Related]  

  • 36. Experience with the use of a first-line regimen of stavudine, lamivudine and nevirapine in patients in the TREAT Asia HIV Observational Database.
    Zhou J; Paton NI; Ditangco R; Chen YM; Kamarulzaman A; Kumarasamy N; Lee CK; Li PC; Merati TP; Phanuphak P; Pujari S; Vibhagool A; Zhang F; Chuah J; Frost KR; Cooper DA; Law MG
    HIV Med; 2007 Jan; 8(1):8-16. PubMed ID: 17305926
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Triple-drug therapy may mean lifelong commitment.
    AIDS Alert; 1999 Jan; 14(1):3-5. PubMed ID: 11366090
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FDA grants tentative approval to first generic version of antiretroviral Viread.
    AIDS Patient Care STDS; 2008 Jan; 22(1):86. PubMed ID: 18453039
    [No Abstract]   [Full Text] [Related]  

  • 39. A randomized trial to evaluate continuation versus discontinuation of lamivudine in individuals failing a lamivudine-containing regimen: the COLATE trial.
    Fox Z; Dragsted UB; Gerstoft J; Phillips AN; Kjaer J; Mathiesen L; Youle M; Katlama C; Hill A; Bruun JN; Clumeck N; Dellamonica P; Lundgren JD;
    Antivir Ther; 2006; 11(6):761-70. PubMed ID: 17310820
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Testimony on accelerated approval.
    Hogan C
    GMHC Treat Issues; 2003 Nov; 17(11):12. PubMed ID: 14717108
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.